Adriano Venditti

Use of Peripheral Blood to Measure Residual Disease by Flow Cytometry in Adult Acute Myeloid Leukemia: Final Report of the Prospective GIMEMA AML1310 Trial

Luca Maurillo, Francesco Buccisano, Raffaele Macarone Palmieri, Marta Cipriani et autres

it (code pays fourni par la source)

Real‐world outcomes of venetoclax plus hypomethylating agents in unfit acute myeloid leukaemia: Results of the GIMEMA AML2320 trial

Raffaele Macarone Palmieri, Alfonso Piciocchi, Stefano Soddu, Marco Frigeni et autres

Venetoclax (VEN) plus hypomethylating agents (HMAs) represents the standard of care for newly diagnosed acute myeloid leukaemia (AML) patients unfit for intensive chemotherapy, but prospective real-world observational data outside randomized clinical trials remain limited. The Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) AML2320 …

it (code pays fourni par la source)

De novo JAK2 ‐mutated acute myeloid leukaemia: Clinical outcomes and molecular features

Luca Guarnera, Emiliano Fabiani, Eleonora Lumia, Paola Ricci et autres

it (code pays fourni par la source)

An Italian cartography of VEXAS‐related thrombosis

Giorgia Ranucci, Maria Rosaria Pascale, Vittorio Forte, Elisa Diral et autres

Abstract Thrombotic events (TEs) occur in up to 40% of patients with vacuoles, E1 enzyme, X‐linked, autoinflammatory, and somatic (VEXAS) syndrome, but data on its clinical‐genomics features and anticoagulation strategies are limited. To gain more insight into this, we conducted a two‐step …

it, us (code pays fourni par la source)

RBC depletion with Gelofusine in allogeneic hematopoietic stem cell transplantation

Antonio Bruno, Gianpaolo Del Proposto, Gaspare Adorno, Michele Abignente et autres

Data sharing not applicable to this article as no datasets were generated or analysed during the current study.

it (code pays fourni par la source)

Real‐Life Study on Gilteritinib‐Related Infections ( GilteRInf ): An Italian SEIFEM Study

Elisa Buzzatti, Irene Terrenato, Martina Tomassi, Federica Lessi et autres

my, it (code pays fourni par la source)

APL‐like subset within NPM1 ‐mutated AML: A distinct immunophenotype correlating with early vascular complications

Francesco Mannelli, Francesca Crupi, Sara Bencini, Michaela Feuring et autres

Abstract Among NPM1 ‐mutated acute myeloid leukemia (AML) ( NPM1 mut ), a distinct subtype has been described with an immunophenotypic profile resembling acute promyelocytic leukemia (APL‐like). In this retrospective multicenter study including 384 NPM1 mut AML patients, we identified 95 (24.7%) …

it, de (code pays fourni par la source)

Lipegfilgrastim for primary prophylaxis of febrile neutropenia in patients treated for advanced-stage classical hodgkin lymphoma: successful outcomes from a multicenter cohort study

Claudia Giordano, M. Picardi, Fabiana Esposito, A. Vincenzi et autres

In patients with classical Hodgkin lymphoma (c-HL) undergoing ABVD chemotherapy for advanced disease, the optimal strategy to prevent febrile neutropenia (FN)—defined as fever ≥ 38 °C with absolute neutrophil count (ANC) < 1000/mm³—remains debated. Possible prophylaxis approaches include: i) secondary prophylaxis with …

it (code pays fourni par la source)

Co-occurrence of angioimmunoblastic T-cell lymphoma and aggressive-refractory plasma-cell neoplasm: Two new cases and literature review

M. Christina Cox, Claudia Seimonte, Erica Giacobbi, Gianmario Pasqualone et autres

Angioimmunoblastic T-cell lymphoma (AITL) is a rare and aggressive peripheral T-cell lymphoma of T-follicular helper (TFH) cell origin, characterized by systemic manifestations, immune dysregulation, and frequent secondary B-cell proliferations. While Epstein-Barr virus (EBV)-related diffuse large B-cell lymphoma develops in up to 20% …

it (code pays fourni par la source)

Pathogenetic mechanism of macular edema during a treatment with ibrutinib: a case presentation.

Cristina Mauro, Livio Pupo, Lucia Cardillo, Fabiana Esposito et autres

Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are low-grade non-Hodgkin lymphomas characterized by monoclonal B lymphocytes. Bruton tyrosine kinase inhibitors represent the first-line treatment for symptomatic CLL/SLL. Here we report a case of a patient with SLL treated with ibrutinib …

it (code pays fourni par la source)

Incidence and Characteristics of Perianal Infections in CPX-351-Treated AML Patients

Elisa Buzzatti, Cristina Mauro, Cristiano Tesei, Giovangiacinto Paterno et autres

Background: Perianal infections (PIs) are a serious threat in patients with acute myeloid leukemia (AML). While CPX-351 is designed to reduce gastrointestinal toxicity, its impact on the incidence of PIs is unknown. This study aims to evaluate the incidence and characteristics of …

it, us (code pays fourni par la source)

2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working Party

Jacqueline J Cloos, Peter J.M. Valk, Christian Thiede, Konstanze Döhner et autres

ABSTRACT: Measurable residual disease (MRD) monitoring has become a critical component in the management of acute myeloid leukemia (AML), to inform prognosis, guide therapy, and serve as a key end point in clinical trials. The 2025 update of the MRD guideline provides …

nl, de, us, pl, au, fr, it, in, gb, il, ca, br, be (code pays fourni par la source)